ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 1999, p Vol. 43, No. 5. Copyright 1999, American Society for Microbiology. All Rights Reserved.
|
|
- Earl Hubbard
- 5 years ago
- Views:
Transcription
1 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 1999, p Vol. 43, No /99/$ Copyright 1999, American Society for Microbiology. All Rights Reserved. Safety and Pharmacokinetics of an Intramuscular Monoclonal Antibody (SB ) against Respiratory Syncytial Virus (RSV) in Infants and Young Children at Risk for Severe RSV Disease H. CODY MEISSNER, 1 * JESSIE R. GROOTHUIS, 2 WILLIAM J. RODRIGUEZ, 3 ROBERT C. WELLIVER, 4 GEOFF HOGG, 5 PETER H. GRAY, 6 RICHARD LOH, 7 ERIC A. F. SIMOES, 8 PETER SLY, 7 ANN K. MILLER, 9 ALICE I. NICHOLS, 9 DIANE K. JORKASKY, 9 DANIEL E. EVERITT, 9 AND KATHLEEN A. THOMPSON 9 Department of Pediatrics, New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts ; Ross Products Division, Columbus, Ohio ; Department of Pediatrics, National Children s Medical Center, Washington, D.C ; Department of Pediatrics, Children s Hospital of Buffalo, Buffalo, New York ; Royal Children s Hospital, Parkville, Victoria, 5 The Mater Misercordias Public Hospitals, South Brisbane, Queensland, 6 and Princess Margaret Hospital, Subiaco, Perth, Western Australia, 7 Australia; Department of Pediatrics, University of Colorado School of Medicine and Children s Hospital, Denver, Colorado ; and SmithKline Beecham, Philadelphia, Pennsylvania Received 1 June 1998/Returned for modification 5 September 1998/Accepted 25 February 1999 We conducted a multicenter, double-blind, placebo-controlled, randomized trial of a humanized monoclonal antibody against a respiratory syncytial virus (RSV) fusion protein (SB ) to evaluate its safety, pharmacokinetics, and fusion inhibition and neutralization titers. Forty-three infants who were either delivered prematurely (<35 weeks gestation) or exhibited bronchopulmonary dysplasia were administered either single or repeat (two doses, 8 weeks apart) intramuscular injections of SB at a concentration of 0.25, 1.25, 5.0, or 10.0 mg/kg or of a placebo. Four of 229 adverse events were considered related to the study drug, including purpura (n 3) and thrombocytosis (n 1). No subject developed a detectable level of anti-sb antibody. Approximately 1 week after administration of the second dose of SB at 10 mg/kg, the mean plasma concentration (n 9) was 68.5 g/ml. The terminal half-life (T 1/2 ) determined by noncompartmental analysis ranged from 22 to 50 days. The population pharmacokinetics for SB following intramuscular administration was appropriately described by a one-compartment model with first-order input and elimination. Higher values for clearance and volume of distribution at steady state were observed for younger patients, with values decreasing to (ml/h)/kg and 161 ml/kg, respectively, by a mean age of 298 days ( 10 months). The mean T 1/2 of SB for the study population was 32.5 days. No other factor (dose, weight, gender, race, premature birth, or bronchopulmonary dysplasia) was observed to alter the population pharmacokinetics of SB in this study of infants and young children. The mean neutralization titer on day 6 was 286, and the mean fusion inhibition titer was 36. At least 57% of subjects dosed at 1.25 to 10.0 mg of SB per kg of body weight who were seronegative at baseline experienced a fourfold or greater increase in fusion inhibition titer. Nine RSV infections were documented during the 16-week course of the study; the numbers of RSV infections were similar for the different regimens, including the placebo. The doses of SB studied may have been insufficient to confer protection against RSV lower respiratory tract disease; these results suggest that additional trials using higher doses of monoclonal antibody for immunoprophylaxis should be considered. Respiratory syncytial virus (RSV) remains one of the most important infectious causes of hospitalization of infants and young children (8). Seasonal outbreaks of RSV disease result in infection in over 90% of children by 2 years of age. The outcome varies from a mild upper respiratory tract illness in approximately 75% of infected infants and children to a severe, life-threatening disease in a small percentage of infected patients. Infants at particular risk of severe disease include prematurely born children, children born with congenital heart disease, and children with chronic lung disease, particularly bronchopulmonary dysplasia (BPD) (10). * Corresponding author. Mailing address: New England Medical Center, Box 321, 750 Washington St., Boston, MA Phone: (617) Fax: (617) cmeissner@es.nemc.org. Present address: Hawthorne Research and Consulting, King of Prussia, PA Despite the importance of RSV as a pathogen in the pediatric age group, options for treatment and prevention of RSV disease are limited. Active immunization to prevent severe RSV disease has not yet proven successful (7). Two clinical trials with a polyclonal, hyperimmune RSV globulin have demonstrated safety and efficacy for prophylaxis in carefully selected children at increased risk for severe RSV infection (6, 13). The results of these clinical trials led to Food and Drug Administration licensure of this RSV antibody-enriched immune globulin in January A second-generation product for immunoprophylaxis against RSV disease is a monoclonal antibody directed against a highly immunogenic RSV surface glycoprotein (12, 15). Monoclonal antibodies to the fusion protein have been shown to be effective in preventing RSV infection in animal models (3, 17 19) and in humans (9). During the respiratory virus season, a multicenter, double-blind, placebo-controlled, 1183
2 1184 MEISSNER ET AL. ANTIMICROB. AGENTS CHEMOTHER. First TABLE 1. Randomization of infants Inoculum (dose, mg/kg) Second randomized trial was conducted with SB , a humanized murine monoclonal antibody directed against the RSV fusion glycoprotein. The primary objectives of this phase I trial were to evaluate the safety and pharmacokinetics of single and repeat intramuscular (i.m.) doses of SB in a pediatric population at risk for severe RSV disease. The secondary objectives included measurement of fusion inhibition titers and neutralization titers and assessment of anti-idiotypic anti-sb antibodies. (This study was presented in part at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 28 September to 1 October 1997.) MATERIALS AND METHODS No. of subjects SB (0.25) SB (0.25) 6 SB (1.25) SB (1.25) 9 SB (5.0) SB (5.0) 8 SB (10.0) SB (10.0) 10 Placebo SB (0.25) 2 Placebo SB (1.25) 2 Placebo SB (5.0) 3 Placebo SB (10.0) 3 a a Includes one subject who was withdrawn from the study prior to receiving the second dose. Patients. Infants and young children less than 37 months of age were eligible for enrollment at one of the seven participating sites if they were born prematurely ( 35 weeks), with a chronological age of 6 months, and/or had a history of BPD. Eligible subjects were required to have a life expectancy of at least 6 months. The protocol was approved by the institutional review board at each site, and informed consent was obtained from all participating families. Exclusion criteria included known preexisting heart, liver, or renal disease; a recognized immune system abnormality; severe respiratory illness requiring assisted ventilation; or previous gamma globulin infusion. Randomization. Participants were randomly assigned to one of four monoclonal antibody dosage groups (0.25, 1.25, 5.0, or 10.0 mg of SB per kg of body weight) or to a placebo group according to a randomization schedule provided by SmithKline Beecham. Each dosage group included at least eight subjects; within each dosage group, at least six infants received SB at the first administration while at least two subjects received the placebo (Table 1). Eight weeks after administration of the first dose, a second i.m. injection was given. Subjects who were randomized to received the monoclonal antibody initially received a repeat dose identical to the initial dose. Subjects who initially received the placebo were crossed over and received SB at a dosage consistent with that for the group to which they were initially assigned. The 8-week dosing interval was identical to the dosing interval examined in an earlier study of adults (unpublished data). Results from this study and an additional trial involving adults demonstrated that plasma levels of SB remain above 10 g/ml 8 weeks after i.m. administration for at least some of the dosages used in the present study (4). This concentration has been associated with protection in murine and rat models of RSV infection in vivo (19). Study drug. SB lyophilate (lot no. U-94045), reconstituted with sterile water to a concentration of 45 mg/ml, and a placebo (a solution containing all components of the active preparation except SB ) were used in this study. Doses of 0.25 and 1.25 mg of SB /kg were administered as single i.m. injections into one thigh muscle. Doses of 5.0 and 10.0 mg/kg were divided and administered as separate injections into each thigh muscle to maintain reasonable injection volumes. Placebo subjects were injected with a volume of placebo equivalent to the volume of active drug that would have been received by a subject of identical weight assigned to that dosage group. At the highest dose, a volume of 0.22 ml of either active drug or placebo per kg was administered. Higher doses of SB were not administered within a randomization regimen until at least three subjects within the regimen s dosage group had received a lower dose and were evaluated through 24 h postdosing (thus ensuring that at least two of the three dosed individuals received the active drug). This evaluation included an assessment of the results of laboratory studies for patient safety, conducted 24 h after injection of the study medication. The following laboratory tests were performed: complete blood count; differential blood count; platelet count; determination of alanine aminotransferase, aspartate aminotransferase, total bilirubin, alkaline phosphatase, and creatinine levels in serum; and urinalysis. Dose escalation was halted and reevaluated in a consultation with the study sponsor upon occurrence of a serious adverse response. Safety parameters. Screening visits included a medical history and physical examination. A physical examination was performed and blood and urine samples were collected for laboratory tests for determination of patient safety prior to administration of each dose of the study medication. Blood and urine samples were also obtained for laboratory testing at 24 h and 2 weeks after administration of the first dose and at 2 weeks after administration of the second dose of the study medication. A physical examination was also performed at the 2-weekpostdose visit. Injection sites were examined for local reactions at approximately 5 min, 2 h, and between 4 and 7 days after each injection. Vital signs were measured prior to and at 15, 30, 45, 60 and 120 min following administration of each dose of the study drug. Blood samples were obtained prior to and approximately 6 days and 2 and 8 weeks following administration of each dose for assessment of the presence of anti-sb antibodies. Plasma was analyzed for anti-sb antibodies by sandwich enzyme-linked immunosorbent assay. Serial dilutions of plasma samples were added to microtiter plates coated with SB Anti-SB antibodies present in plasma were allowed to bind; the sandwiched anti-sb was detected by binding of biotin-labeled SB followed by the use of an avidin-biotinylated alkaline phosphatase system. The positive controls, a bovine monoclonal anti-idiotypic antibody and a rabbit polyclonal anti-sb antibody, were included in each assay. Subjects were monitored during the RSV season for the presence of RSV disease symptoms through biweekly telephone contacts. If a subject developed respiratory symptoms, attempts were made to obtain a nasopharyngeal aspirate, which was tested for the presence of RSV by antigen detection assay. Samples testing positive were transported to a central processing laboratory for RSV culture and titer determination. Pairs of tubes of Hep2 cells (in 1.5 ml of basal medium [Eagle minimal medium supplemented with 2% fetal calf serum, 2% L-glutamine, and 1% penicillin-streptomycin-fungizone]) were each inoculated with 0.2 ml of 10 0 to 10 6 dilutions of the nasopharyngeal aspirate specimen. The inoculated cells were then incubated at 34 C for 3 weeks and observed three times per week for development of cytopathic effects. The maintenance medium was changed two times per week. Observed virus titers were expressed as 50% tissue culture infective doses per milliliter. Pharmacokinetic parameters. For analysis of plasma SB concentrations, venous blood samples were collected in sodium citrate tubes prior to administration of the first dose and at approximately 24 h, 6 days, and 2 and 8 weeks after the first dose of study medication was administered. The 8-week sample was drawn just prior to administration of the second dose. Blood samples were also drawn at approximately 6 days and 2 and 8 weeks after administration of the second dose of the study medication. Plasma SB concentrations were quantified by an enzyme-linked immunosorbent assay based on the simultaneous binding of SB to two bovine anti-idiotypic monoclonal antibodies, B11 and B12 (3). Briefly, SB was captured from plasma in a microtiter plate to which B11 had been bound. The B11-SB complex was then probed with biotinylated B12, forming a sandwich which was detected with horseradish peroxidase-conjugated streptavidin. The lower limit of detection of SB in 10% (vol/vol) phosphate saline buffer was g/ml. A low predose response was noted in one patient in the 1.25-mg/kg group. However, this value had no effect on the data analysis, since all postdosing SB concentrations in this patient were at least 30-fold higher than the predose level. Typical within- and between-run precision values (coefficients of variation) for this assay were 2.8 to 8.4% and 0.8 to 12.9%, respectively. Typical average accuracy values were 94 to 105%. Concentration-time data for each subject in each dose group were analyzed by noncompartmental methods. The area under the plasma concentration-time curve from immediately predose (time zero) to the last quantifiable concentration (AUC 0 t ), the peak concentration of SB (C max ), and the apparent terminal elimination phase half-life (T 1/2 ) were determined for both the first and second doses of SB The AUC for the first dose was calculated by using samples obtained prior to administration of the second dose. The AUC following administration of the second dose (the sum of the AUC for the second dose plus that remaining from the first dose) was calculated by using blood samples obtained immediately before administration of the second dose as well as samples obtained at 6 days and at 2 and 8 weeks after administration of the second dose. The apparent terminal elimination phase rate constant, z, was derived from the log-linear disposition phase of the concentration-time curve by least-squares regression analysis with visual inspection of the data to determine the appropriate number of data points for the calculation of z. At least three points in the terminal elimination phase were required for calculation of z. The AUC 0 t was calculated by using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid. The T 1/2 was calculated as ln 2/ z. The plasma concentration-time data were further analyzed by using nonlinear mixed-effect modeling as implemented in the NONMEM computer program (1, 2). Based on a visual examination of these data and data from a previous study of healthy adults, a one-compartment model with first-order input and elimination was used to describe the data. This model was parameterized in terms of the apparent clearance (CL/F), the volume of distribution at steady state (V SS /F),
3 VOL. 43, 1999 TRIAL OF MONOCLONAL ANTIBODY AGAINST RSV SB TABLE 2. Patient demographics by dosage group Enrollment status Dose (mg/kg) Age at time of enrollment Mean (months) Range (months) 4 to to to to 13 Mean weight at time of enrollment (kg) Male/female ratio 3/5 5/6 3/8 10/3 Race (white/black/other) 7/1/0 7/2/2 7/1/3 11/1/1 RSV risk factor(s) Prematurity BPD plus prematurity BPD alone and the absorption rate (k a ) following i.m. administration. The effects of patient demographics and other factors (dose, age, weight, gender, race, premature birth, and BPD on the pharmacokinetic parameters CL/F and V ss /F were assessed to determine whether these factors should be retained in the final model. To examine the potential effect of these factors on the pharmacokinetics of SB , the value of k a was fixed at liters/h. The primary consideration in selecting which model to use in analyzing the data (including selection of the factors to be included in the model) involved a statistically significant change in the objective function as implemented by Beal and Sheiner (2). For hierarchical models, a difference of 8 in the objective function was assumed to be significant at the 95% level when there was a change of 1 degree of freedom. Nonhierarchical models were assessed by direct comparison of the log likelihood values. The following were also crucial to the selection of a model: (i) assessment of the weighted residual plots showing any variability as featureless random noise; (ii) increased precision in parameter estimates, resulting in smaller values for standard error; and (iii) reduction in estimates of interindividual variances. Pharmacodynamic parameters. Venous blood samples for analysis of fusion inhibition and plasma neutralization antibody titers were obtained prior to administration of each dose and at approximately 6 days and 2 and 8 weeks after administration of SB or the placebo. In vitro microneutralization assays were used to measure the ability of SB to inhibit the growth of RSV (4). Fusion inhibition and plasma neutralization titers were expressed as the reciprocal of the dilution which caused a 50% reduction in the optical density at 450 nm based on regression analysis of the dose titration. TABLE 3. Frequency of RSV-positive episodes by dosage Group No. infected/total (%) p value a 95% CI b Placebo 2/10 (20%) SB mg/kg 2/14 (14%) mg/kg 2/20 (10%) mg/kg 2/19 (11%) mg/kg 1/22 (5%) a Logistic regression analysis was used to compare each group with the placebo group. b CI, confidence interval. RESULTS Enrollment. Forty-three infants and children were enrolled in this study (11 premature infants without BPD and 32 infants with BPD). The subjects ranged in age from 8 days to 33 months and weighted between 1.1 and 15.5 kg (mean, 5.3 kg) at the time of enrollment. The racial demographics were as follows: 74% white, 12% black, 12% Oriental, and 2% other. Forty-two subjects completed the study. One subject was withdrawn due to noncompliance with the follow-up protocol after receiving one 10-mg/kg dose of SB This subject was included in the analysis as if the 10-mg/kg treatment regimen had been completed. The number of subjects who received each treatment regimen is shown in Table 1. The patient demographics as a function of dosage group are shown in Table 2. Although it is difficult to assess homogeneity across dosage groups given the relatively small sample size, it appears that the groups were fairly well balanced in terms of mean age and weight. The racial compositions of the groups were also relatively balanced; participants in all four dosage groups were predominantly white. The gender distributions of the three lowest-dosage groups were similar, with more females being enrolled than males; the highest-dosage group was skewed in the opposite direction. The majority of subjects in each group had chronic lung disease (BPD). Safety results. Single and repeat doses of 0.25 to 10.0 mg of SB per kg were safe and well tolerated. There were no deaths during the study. There were 229 adverse events reported for 41 subjects over the 16 weeks following treatment with the study medication. Thirty-seven adverse events occurred in 10 subjects who received the placebo, and 192 were reported in 35 subjects who received SB Most were mild to moderate in severity. Four adverse events were considered by the investigators to be related to the study drug. These included three episodes of mild to moderate purpura, which occurred in two subjects, and thrombocytosis, which occurred in one subject. The purpura developed at the site of blood sampling. All adverse events had resolved by the end of the study surveillance period. Nineteen laboratory test values were considered clinically relevant by the investigator. Two of these, granulocytopenia and thrombocytosis, were considered to be related to the study medication. The administration of the study drug was not altered in any patient due to side effects. Erythema or induration at the injection site was observed at 30% of placebo injection sites and at 48% of SB injection sites at 5 min postadministration. Most reactions consisted of erythema without induration. No adverse reactions were evident in placebo recipients after 5 min. Eight percent of SB injection sites continued to show a response at 2 h postadministration. No reactions were evident at the final scheduled assessment (between 4 and 7 days postadministration). These reactions were not reported to be associated with obvious pain or discomfort and were not considered by the investigators to be clinically relevant. None of the subjects plasma samples tested positive for anti-sb antibodies. RSV infection. Sixty-five episodes of respiratory illness occurred. During 40 of these episodes, nasopharyngeal specimens were obtained, and RSV was recovered from nine specimens, as shown in Table 3. Although there were fewer RSV infections in the group receiving SB at 10 mg/kg (1 of 22) than in the placebo group (2 of 10), the difference was not statistically significant (P 0.20). Pharmacokinetic evaluation. Following noncompartmental analysis of the SB concentration data, C max values and total exposure (as indicated by the AUC) of SB following i.m. administration increased with increasing dosages of SB (Table 4). All subjects had quantifiable concentrations of SB at the last sampling times for the first and second doses of SB The T 1/2 was calculated only if at least three time-concentration values were present in the terminal phase. This resulted in the T 1/2 being estimated for 21 of 75 concentration-time profiles derived from 43 subjects, ranging from 22 to 50 days. Concentrations of SB were available on days 1 and 6 after the first dose of SB was administered in 19 of the 43 subjects. All 19 of the subjects had higher concentrations on day 6 than on day 1. Mean concentrations in specimens obtained on day 56 ( 7 days), as shown in Table 4, ranged from 0.50 to 21.1 g/ml for dosages of 0.25
4 1186 MEISSNER ET AL. ANTIMICROB. AGENTS CHEMOTHER. TABLE 4. Pharmacokinetic parameters for SB after single and repeat i.m. doses Parameter Single or repeat administration Mean value SD (n) at a dose of (mg/kg) a : C max ( g/ml) Single (8) (11) (11) (13) Repeat (6) (9) (8) (9) Concn, day 56 ( g/ml) Single (8) (9) (10) (11) Repeat (6) (7) (6) (8) AUC 0 t ( g h/ml) Single 1, (8) 5,611 1,655 (11) 17,197 10,912 (11) 35,794 10,098 (13) Repeat 1, (6) 7,166 2,556 (9) 23,059 14,078 (7) 57,363 10,483 (9) a Values are provided for concentrations obtained on day 56 ( 1 week). Parenthetic. to 10 mg/kg. Mean plasma SB concentrations following single and repeat i.m. doses are shown in Fig. 1. Based on NONMEM analysis, the SB plasma concentration-time data in this patient population were adequately described by a one-compartment model with first-order input. A covariate evaluation showed that the CL/F and V SS /F values were higher for younger patients, with values decreasing with increasing age to (ml/h)/kg and 161 ml/ kg, respectively, by a mean age of 298 days ( 10 months). The corresponding T 1/2 for a mean age of 298 days was 32.5 days. The relationship between age and CL/F was described as follows: CL/F (age/298) For V SS /F, the model which included age was described as follows: V SS /F 161 (age/298) The exponential equations permitted predictions for CL/F and V SS /F to increase for newborns through the age of 298 days and to level off as the age increased beyond 298 days. Between-subject variabilities described by coefficients of variation for CL/F and V SS /F were estimated to be 34 and 33%, respectively. No other factor (dose, weight, gender, race, premature birth, or BPD) was observed to alter the population pharmacokinetics of SB in this study of infants and young children. Dose linearity is supported by the fact that changes in CL/F and V SS /F were not related to dose amounts. Pharmacodynamic evaluation. The mean and median neutralization and fusion inhibition antibody titers on day 6 are shown, in comparison to the corresponding predose titers, in Table 5. Increases in most of the titers were observed for recipients of each of the four dosing regimens. In the 10 placebo recipients, median titers did not significantly change between predose and 6-day-postdose specimens. Among infants who received a dose of 10 mg/kg, there was typically a two- to fourfold increase over predose titers. The wide range of pre- Downloaded from on August 22, 2018 by guest FIG. 1. Mean SB concentrations, standard deviations, versus time for subjects receiving doses of 0.25 mg/kg (E), 1.25 mg/kg ( ), 5 mg/kg ( ), or 10 mg/kg ({).
5 VOL. 43, 1999 TRIAL OF MONOCLONAL ANTIBODY AGAINST RSV SB TABLE 5. Neutralization and fusion inhibition antibody titers Antibody titer for study group administered: Titer type 10 mg/kg (n 11) 5 mg/kg (n 11) dose neutralization and fusion inhibition antibody titers among infants in different dosing groups explains at least some of the variation in peak titers after dosing. To further evaluate the change in the levels of both neutralizing antibodies and fusion inhibition antibodies, the same data were analyzed as ratios of the concentrations on day 6 to the predose titers (Table 6). This analysis also shows the difference between predose and day 6 concentrations in those subjects who were seronegative prior to the first dose. Although the number of SB recipients who were seronegative before administration of the first dose was small in each category, the majority of seronegative subjects who received SB at a dose of 1.25 mg/kg or higher demonstrated more than a fourfold increase in neutralizing and fusion inhibition antibody titers on day 6. DISCUSSION In the absence of a safe and effective vaccine, passive immunoprophylaxis holds the greatest promise for the prevention of severe RSV illness in high-risk children. Studies have shown that immunoprophylaxis with a polyclonal, hyperimmune RSV globulin is effective in attenuating RSV disease both in animal SB at dose of: 1.25 mg/kg (n 9) 0.25 mg/kg (n 7) Placebo (n 10) Neutralization titer Mean (SD) Predose 155 (66) 228 (89) 704 (338) 278 (119) 1,255 (984) Day 6 postdose 286 (89) 375 (102) 508 (185) 304 (127) 1,146 (985) Median (range) Predose 67 (2 675) 109 (2 877) 234 (2 3,098) 234 (2 855) 129 (2 10,000) Day 6 postdose 131 (32 961) 242 (32 1,130) 310 (59 1,890) 132 (11 770) 104 (2 10,000) Fusion titer Mean (SD) Predose 11 (4) 22 (13) 35 (19) 52 (25) 26 (15) Day 6 postdose 36 (9) 96 (41) 76 (33) 72 (33) 12 (5) Median (range) Predose 2 (2 37) 2 (2 137) 18 (2 179) 48 (2 189) 16 (2 160) Day 6 postdose 34 (2 86) 52 (2 467) 45 (2 268) 39 (2 233) 2 (2 42) Titer increase seen models and in high-risk infants and children. However, there are several disadvantages to this product, including the need for intravenous administration, the fluid volume associated with its administration, the less-than-complete protection against RSV disease achieved, and the issue of safety in children with cyanotic heart disease (11). An effective monoclonal antibody can be administered i.m., thereby avoiding many of these difficulties. Monoclonal antibodies of purely murine origin have not been widely used in clinical trials due to concerns with regard to the development of anti-murine antibodies. Substitution of human sequences for the murine sequences within the nonantigen-binding region of the molecule results in a lower degree of immunogenicity relative to that of unmodified murine monoclonal antibodies. In the present trial, single and repeat doses of 0.25 to 10.0 mg of SB , a humanized murine monoclonal antibody against the RSV fusion protein, per kg were safe and well tolerated when administered i.m. to highrisk infants. Evaluation of the local and systemic anti-sb immune response failed to reveal evidence of an immune reaction against this humanized antibody. These results are similar to those of previous studies of healthy male subjects TABLE 6. Numbers and percentages of subjects with two- or fourfold increases in antibody titers. No. of subjects with indicated titer increase/no. tested (%) for group administered: SB at dose of: 10 mg/kg 5 mg/kg 1.25 mg/kg 0.25 mg/kg Neutralization ratio All subjects 2-fold 5/11 (45) 5/11 (45) 3/9 (33) 2/7 (29) 1/10 (10) 4-fold 4/11 (36) 4/11 (36) 2/9 (22) 2/7 (29) 1/10 (10) Seronegative subjects, predose 2-fold 3/3 (100) 2/2 (100) 2/2 (100) 2/2 (100) 1/2 (50) 4-fold 3/3 (100) 2/2 (100) 2/2 (100) 2/2 (100) 1/2 (50) Fusion ratio All subjects 2-fold 6/11 (55) 7/11 (64) 5/9 (56) 1/7 (14) 1/10 (10) 4-fold 5/11 (45) 5/11 (45) 5/9 (56) 0/7 (0) 0/10 (0) Seronegative subjects, predose 2-fold 4/7 (57) 5/8 (63) 2/3 (67) 0/3 (0) 0/4 (0) 4-fold 4/7 (57) 5/8 (63) 2/3 (67) 0/3 (0) 0/4 (0) Placebo
6 1188 MEISSNER ET AL. ANTIMICROB. AGENTS CHEMOTHER. who received single and multiple doses of SB and did not develop a detectable anti-idiotypic reaction (4). Another humanized RSV monoclonal antibody, directed against the F protein, showed a similar lack of immunogenicity (16). Although the number of sampling times in this study was limited (n 7) in comparison to many studies examining pharmacokinetics, sufficient information was available to provide individual values of C max and AUC 0 t by utilizing noncompartmental pharmacokinetic methods. However, parameter estimates for AUC 0 t and C max should be considered as approximations of the values that would be obtained with a more intensive sampling schedule. By the use of population modeling, estimates of CL/F and V SS /F were obtainable. The predicted CL/F of (ml/h)/kg for the mean age of 298 days is similar to values of intravenous clearance (CL) reported for healthy adults who were administered intravenous doses of SB (15). In this earlier study, mean CL values ranged from to (ml/h)/kg for similar doses of 0.25 to 10.0 mg/kg. Mean estimates for V SS /F from the earlier, intravenous study of healthy adults ranged from 87.5 to 104 ml/kg for doses of 0.25 to 10.0 mg/kg. This is in contrast to a mean V ss /F of 161 ml/kg for the present study population. These differences could be in part due to the larger proportion of total and extracellular body water in infants and young children (5). Analysis of plasma neutralization and fusion inhibition antibody levels following administration of a single dose of the study medication suggests that doses of as little as 1.25 mg of SB per kg may be associated with some increase in antiviral activity. However, given the relatively low neutralization and fusion inhibition antibody titers that were achieved with the highest dosing regimen, it is not surprising that differences in RSV attack rates were not observed. Also, the high predose neutralization-antibody titer in placebo recipients may have conferred some degree of protection, making it difficult to detect a difference in RSV infection rates between groups. Experience with a polyclonal, hyperimmune RSV globulin indicates that serum neutralizing-antibody titers of greater than 1:200 are necessary to limit RSV replication in the lower respiratory tract. Because of the presence of functionally distinct populations among the RSV-neutralizing antibodies in a polyclonal antibody preparation, only a subset of neutralizing antibodies may actually be protective (14). In this trial, the absence of a cumulative effect on antibody concentration that would be derived from serial doses of SB also may have contributed to the lack of an effect on RSV infection rates. However, the lack of toxicity and the relative ease of i.m. administration justify further consideration of RSV prophylaxis with a monoclonal antibody. ACKNOWLEDGMENTS We thank Danuta Herzyk for assessment of the anti-sb response and Sandra Griego for assistance with analysis of data relating to titers. REFERENCES 1. Beal, S. L., and L. B. Sheiner The NONMEM system. Am. Stat. 34: Beal, S. L., and L. B. Sheiner and NONMEM users guide, parts I to VI. University of California, San Francisco. 3. Davis, C. B., T. W. Hepburn, J. J. Urbanski, D. C. Kwok, T. K. Hart, D. J. Herzyk, S. G. Demuth, M. Leland, and G. R. Rhodes Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19. Drug Metab. Dispos. 23: Everitt, D. E., C. B. Davis, K. Thompson, R. DiCicco, B. Ilson, S. G. Demuth, D. J. Herzyk, and D. K. Jorkasky The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers. J. Infect. Dis. 174: Green, T. P., and B. L. Mirkin Clinical pharmacokinetics: pediatric considerations, p In L. Z. Bennet, N. Massoud, and J. G. Gambertoglio (ed.), Pharmacokinetic basis for drug treatment. Raven Press, New York, N.Y. 6. Groothuis, J. R., E. A. F. Simoes, J. J. Levin, et al Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and children. N. Engl. J. Med. 329: Hall, C. B Prospects for a respiratory syncytial virus vaccine. Science 265: Heilman, C. A Respiratory syncytial and parainfluenza viruses. J. Infect. Dis. 161: IMPACT-RSV Study Group Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from RSV infection in high-risk infants. Pediatrics 102: Meissner, H. C., R. C. Welliver, S. A. Chartrand, D. R. Fulton, W. J. A. Rodriguez, and J. R. Groothuis Prevention of respiratory syncytial virus infection in high risk infants: consensus opinion on the role of immunoprophylaxis with respiratory syncytial virus hyperimmune globulin. Pediatr. Infect. Dis. J. 15: Meissner, H. C., and J. R. Groothuis Immunoprophylaxis and control of RSV disease. Pediatrics 100: Olmsted, R. A., N. Elango, G. A. Prince, B. R. Murphy, P. R. Johnson, B. Moss, and P. Collins Expression of the F glycoprotein of respiratory syncytial virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc. Natl. Acad. Sci. USA 83: PREVENT Study Group Reduction of RSV hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 99: Siber, G. R., J. Leszczynski, V. Pena-Cruz, C. Ferren-Gardner, R. Anderson, V. G. Hemming, E. E. Walsh, J. Burns, K. McIntosh, R. Gonin, and L. J. Anderson Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay. J. Infect. Dis. 165: Stott, E. J., G. Taylor, L. A. Ball, K. Anderson, K.K.-Y. Young, A. M. Q. King, and G. W. Wertz Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus. J. Virol. 61: Subramanian, K. N. S., L. E. Weisman, T. Rhodes, R. Ariagno, P. J. Sanchez, J. Steichen, L. B. Givner, T. L. Jennings, F. H. Top, Jr., D. Carlin, and E. Connor Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr. Infect. Dis. J. 17: Taylor, G., E. J. Stott, M. Hughes, and A. P. Collins Respiratory syncytial virus in mice. Infect. Immun. 43: Walsh, E. E., J. J. Schlesinger, and M. W. Brandriss Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. Infect. Immun. 43: Wyde, P. R., D. K. Moore, T. Hepburn, C. L. Silverman, T. G. Porter, M. Gross, G. Taylor, S. G. Demuth, and S. B. Dillon Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats. Pediatr. Res. 38:
Drug Utilization Review: Palivizumab (Synagis ; Medimmune)
Background Respiratory syncitial virus (RSV) is a highly contagious virus that is estimated to infect nearly all children by 3 years of age, and is the leading cause of serious lower respiratory tract
More information1.0 Abstract. Palivizumab P Study Results Final
1.0 Abstract Title: Prospective, Multi-Center, Observational Program to Assess RSV Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis
More informationPassive vaccination as a global strategy for preventing RSV disease in infants. Filip Dubovsky MD MPH FAAP MedImmune March 2016
Passive vaccination as a global strategy for preventing RSV disease in infants Filip Dubovsky MD MPH FAAP MedImmune March 2016 Outline for Presentation Rationale for passive immunization for RSV prophylaxis
More informationRecombinant, Insect Cell-Derived RSV Nanoparticle Vaccine
Recombinant, Insect Cell-Derived RSV Nanoparticle Vaccine Gregory Glenn Chief Medical Officer MVADS-Copenhagen 4 July 2012 1 Agenda for RSV Discussion Overview of Insect Cell Technology Respiratory Syncytial
More information(Accepted 20 April 1989)
J. gen. Virol. (1989), 7, 2185-219. Printed in Great Britain 2185 Key words: RSV/vaccinia virus/antibody-mediated immune suppression Immunosuppression of the Antibody Response to Respiratory Syncytial
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL HCN Exception/Other PALIVIZUMAB SYNAGIS 18564 Synagis may be covered during the RSV season from October 15, 2017 and March 31, 2018. If the PA is received prior to October 15, 2017,
More informationClinical Policy: Palivizumab (Synagis) Reference Number: ERX.SPA.124 Effective Date: Last Review Date: 08.17
Clinical Policy: (Synagis) Reference Number: ERX.SPA.124 Effective Date: 10.01.16 Last Review Date: 08.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationSynagis. Synagis (palivizumab) Description. Section: Prescription Drugs Effective Date: July 1, 2016
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.20.04 Section: Prescription Drugs Effective Date: July 1, 2016 Subject: Synagis Page: 1 of 5 Last Review
More informationTrends in Chronologic Age and Infant Respiratory Syncytial Virus Hospitalization: an 8-Year Cohort Study
Adv Ther (2011) 28(3):195-201. DOI 10.1007/s12325-010-0106-6 ORIGINAL RESEARCH Trends in Chronologic Age and Infant Respiratory Syncytial Virus Hospitalization: an 8-Year Cohort Study Jon P. Fryzek William
More informationRespiratory Syncytial Virus (RSV) Just another virus or not? Doris Makari, MD Senior Director, Scientific Affairs Nov 16th, 2012
Respiratory Syncytial Virus (RSV) Just another virus or not? Doris Makari, MD Senior Director, Scientific Affairs Nov 16th, 2012 Key Points RSV is not just another virus to infants RSV is the leading cause
More informationRSV F Nanoparticle Vaccine: Update Gregory M. Glenn M.D., SVP R&D
RSV F Nanoparticle Vaccine: Update Gregory M. Glenn M.D., SVP R&D Summary of Findings in Recent Clinical Trials International Society of Vaccines October 26, 2014 1 www.novavax.com 2 The Problem with RSV
More informationRespiratory Syncytial Virus Prophylaxis Program Saskatchewan Protocol Season
Respiratory Syncytial Virus Prophylaxis Program Saskatchewan Protocol 2018-2019 Season Respiratory Syncytial Virus (RSV) is the most common cause of lower respiratory tract illness and hospitalization
More information(For National Authority Use only)
Page 2 Medlmmune, Inc. Name ofactive Ingredient: PROTOCOL SYNOPSIS Title: A Phase II Study ofthe Safety, Tolerance,Phannacokinetics,and Effect on Viral Load in Tracheal Aspirates ofmedi-493, a Humanized
More informationDisclosures. Learning Objectives. Modification of RSV Prophylaxis Recommendations in the 2009 Red Book Why Was it Done, and What Does it Mean for You?
Modification of RSV Prophylaxis Recommendations in the 2009 Red Book Why Was it Done, and What Does it Mean for You? David W. Kimberlin, M.D. Disclosures I have no actual or potential conflict of interest
More information1. TITLE PAGE Study Title:
1. TITLE PAGE Study Title: A Randomized, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Thrombocytopenic Subjects with Immune (Idiopathic) Thrombocytopenic Purpura
More informationDrug Use Evaluation: Synagis (palivizumab) Summary of Findings:
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Drug Use Evaluation: Synagis (palivizumab) Summary
More informationA cost-benefit analysis of respiratory syncytial virus hyperimmune globulin (RSV-IVIG) in high-risk infants Oelberg D, Reininger M, Van Eeckhout J
A cost-benefit analysis of respiratory syncytial virus hyperimmune globulin (RSV-IVIG) in high-risk infants Oelberg D, Reininger M, Van Eeckhout J Record Status This is a critical abstract of an economic
More informationWake Forest Baptist Medical Center Guideline for Use of Ribavirin in the Treatment of Respiratory Syncytial Virus (RSV) Infection
Wake Forest Baptist Medical Center Guideline for Use of Ribavirin in the Treatment of Respiratory Syncytial Virus (RSV) Infection General Information Aerosolized ribavirin has been shown in limited clinical
More informationWake Forest Baptist Medical Center Guideline for Use of Ribavirin in the Treatment of Respiratory Syncytial Virus (RSV) Infection
Wake Forest Baptist Medical Center Guideline for Use of Ribavirin in the Treatment of Respiratory Syncytial Virus (RSV) Infection General Information Aerosolized ribavirin has been shown in limited clinical
More informationTexas Vendor Drug Program Fee-For-Service Medicaid Synagis Authorization Request
Form 1033 September 2017-E Texas Vendor Drug Program Fee-For-Service Medicaid Synagis Authorization Request About Human Respiratory Syncytial Virus (RSV) causes respiratory tract infections and serious
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Synagis Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Synagis (palivizumab) Prime Therapeutics will review Prior Authorization Prior Authorization
More informationNETSCC, HTA 26th July 2009
NETSCC, HTA 26 th July 2009 HTA 06/29/02 1 Title of the project: Palivizumab for immunoprophylaxis of respiratory syncitial virus (RSV) bronchiolitis in high risk infants, additional subgroup analysis
More informationA cost-benefit analysis of RSV prophylaxis in high-risk infants Schrand L M, Elliott J M, Ross M B, Bell E F, Mutnick A H
A cost-benefit analysis of RSV prophylaxis in high-risk infants Schrand L M, Elliott J M, Ross M B, Bell E F, Mutnick A H Record Status This is a critical abstract of an economic evaluation that meets
More informationSYNAGIS (palivizumab) injection, for intramuscular use Initial U.S. Approval: 1998
US-10672 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SYNAGIS safely and effectively. See full prescribing information for SYNAGIS. SYNAGIS (palivizumab)
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Synagis 50 mg powder and solvent for solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains
More informationEU Regulatory Perspective on RSV vaccines
EU Regulatory Perspective on RSV vaccines EU Perspective No RSV-specific guideline in the EU There is no established EU (i.e. CHMP) position CHMP scientific advice has been given, which reflects current
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Synagis) Reference Number: CP.PHAR.16 Effective Date: 08.01.09 Last Review Date: 05.18 Line of Business: Commercial, Medicaid, HIM-Medical Benefit Revision Log See Important Reminder
More informationABBVIE. season. season.
08-15 Synagis ABBVIE NAME OF THE MEDICINAL PRODUCT Synagis 100 mg powder for solution for injection Synagis 50 mg powder for solution for injection QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains
More informationNova Scotia Guidelines for Respiratory Syncytial Virus Infection Prophylaxis ( )
5850/5980 University Avenue PO Box 9700 Halifax, NS B3K 6R8 Canada Tel: 902-470-8888 www.iwk.nshealth.ca Oct 14 Nova Scotia Guidelines for Respiratory Syncytial Virus Infection Prophylaxis (2014-2015)
More informationRE: Season for Respiratory Syncytial Virus Prophylaxis for High-Risk Infants
Ministr y o f He alth and Lon g-term Ca re Ontario Public Drug Programs Division Drug Programs Delivery Branch 3 rd Floor, 5700 Yonge Street Toronto ON M2M 4K5 Telephone: (416) 327-8109 Toll Free: 1-866-811-9893
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Tue, 13 Nov 2018 01:59:14 GMT) CTRI Number Last Modified On 14/09/2016 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
More information1.0 Abstract. Title. Synagis liquid 50 mg, 100 mg for Intramuscular Injection: Special Investigation in Immunocompromised Children with Synagis
1.0 Abstract Title Synagis liquid 50 mg, 100 mg for Intramuscular Injection: Special Investigation in Immunocompromised Children with Synagis Keywords Palivizumab, respiratory syncytial virus, immunocompromised
More informationA Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Clostridium difficile
A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Clostridium difficile vaccine administered with or without Aluminum Hydroxide, in a 3-Dose Regimen in Healthy Adults Aged 50
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Pasi KJ, Rangarajan S, Georgiev P, et al. Targeting of antithrombin
More informationASSESSING THE EFFICACY AND SAFETY OF NORMAL INTRAVENOUS IMMUNOGLOBULIN PRODUCTS FOR MARKETING AUTHORISATIONS
ASSESSING THE EFFICACY AND SAFETY OF NORMAL INTRAVENOUS IMMUNOGLOBULIN PRODUCTS FOR MARKETING AUTHORISATIONS Guideline Title Assessing the Efficacy and Safety of Normal Intravenous Immunoglobulin Products
More informationMedical Assistance Division Medicaid Drug Utilization Review Newsletter
Medical Assistance Division Medicaid Drug Utilization Review Newsletter Volume 8 Issue 4 4th Quarter 2014 Introduction American Academy of Pediatrics Issues New Guidance on Use of Synagis Felice R. Slaughter
More informationMouse TNF-α ELISA MAX Set Deluxe
Mouse TNF-α ELISA MAX Set Deluxe Cat. No. 430904 (5 plates) 430905 (10 plates) 430906 (20 plates) ELISA Set for Accurate Cytokine Quantification from Cell Culture Supernatant, Serum, Plasma or Other Body
More informationcolorimetric sandwich ELISA kit datasheet
colorimetric sandwich ELISA kit datasheet For the quantitative detection of human IL6 in serum, plasma, cell culture supernatants and urine. general information Catalogue Number Product Name Species cross-reactivity
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Synagis) Reference Number: CP.HNMC.159 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationRSV Prevention in Québec Season
RSV Prevention in Québec 2017 2018 Season Marc H. Lebel, MD, FRCPC Infectious-Diseases Service Dr. Marc Lebel Pediatrician infectiologist at the Sainte Justine Hospital since 1989 Founded the infectious
More informationH-ferritin (Human) ELISA Kit
H-ferritin (Human) ELISA Kit Catalog Number KA0211 96 assays Version: 04 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Background... 3 Principle of
More informationClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 08/04/2013. ClinicalTrials.gov ID: NCT
ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 08/04/2013 ClinicalTrials.gov ID: NCT01237340 Study Identification Unique Protocol ID: EMR 701048-009 Brief Title:
More informationMedImmune RSV Surveillance
MedImmune RSV Surveillance WHO Meeting of Mid-term Review of the RSV Surveillance Pilot Based on the Global Influenza Surveillance & Response System 18 20 December 2017 PAHO, Washington DC, USA Mark T.
More informationUse this calendar to help schedule dosing and office appointments for your patients. Key:
0-0 DOSING CALENDAR EVERY DAYS* Use this calendar to help schedule dosing and office appointments for your patients. How to use -day dosing: Key: Locate initial date on calendar Move one box down (This
More informationcolorimetric sandwich ELISA kit datasheet
colorimetric sandwich ELISA kit datasheet For the quantitative detection of human HER2 in serum, plasma, cell culture supernatants and urine. general information Catalogue Number Product Name Species cross-reactivity
More informationBIOEQUIVALENCE TRIAL INFORMATION FORM (Medicines and Allied Substances Act [No. 3] of 2013 Part V Section 39)
ZAMRA BTIF BIOEQUIVALENCE TRIAL INFORMATION FORM (Medicines and Allied Substances Act [No. 3] of 2013 Part V Section 39) The Guidelines on Bioequivalence Studies to be consulted in completing this form.
More informationProgress toward a vaccine for maternal immunization to prevent Respiratory Syncytial Virus Lower Respiratory Tract Illness (RSV LRTI) in infants
Progress toward a vaccine for maternal immunization to prevent Respiratory Syncytial Virus Lower Respiratory Tract Illness (RSV LRTI) in infants November 2018 Safe harbor statement Certain information,
More informationThe RSV season usually runs from October to March each year, whilst the pre-season is typically defined as the months between April and September.
The RSV season usually runs from October to March each year, whilst the pre-season is typically defined as the months between April and September. A multi-disciplinary team (MDT) meeting at the end of
More informationcolorimetric sandwich ELISA kit datasheet
colorimetric sandwich ELISA kit datasheet For the quantitative detection of human IL1-beta in serum, plasma and cell culture supernatants. general information Catalogue Number Product Name Species cross-reactivity
More informationGuideline for Bioequivalence Studies of Generic Products. December 22, 1997
Guideline for Bioequivalence Studies of Generic Products December 22, 1997 Index Section 1: Introduction Section 2: Terminology Section 3: Tests A. Oral conventional dosage forms and enteric coated products
More informationPharmacokinetics. Processes, Mathematics, and Applications. Second Edition. Peter G. Welling. Institut de Recherche Jouveinal
Pharmacokinetics Processes, Mathematics, and Applications Second Edition Peter G. Welling Institut de Recherche Jouveinal ACS Professional Reference Book American Chemical Society Washington, DC Contents
More informationPrevention of Serious Respiratory Syncytial Virus-Related Illness. II: Immunoprophylaxis
Adv Ther (2011) 28(2):110-125. DOI 10.1007/s12325-010-0101-y REVIEW Prevention of Serious Respiratory Syncytial Virus-Related Illness. II: Immunoprophylaxis Jessie R. Groothuis J. Michael Hoopes Val G.
More informationRegulatory considerations for initiating paediatric trials with RSV antivirals
Regulatory considerations for initiating paediatric trials with RSV antivirals Irmgard Eichler European Medicines Agency Expert meeting on RSV therapeutics March 2016 An agency of the European Union In
More informationICH Considerations. Oncolytic Viruses September 17, 2009
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH Considerations Oncolytic Viruses September 17, 2009 1. Introduction Oncolytic viruses
More informationMouse SerpinF2 ELISA Pair Set
Mouse SerpinF2 ELISA Pair Set Catalog Number : SEK50167 To achieve the best assay results, this manual must be read carefully before using this product and the assay is run as summarized in the General
More informationNotes: A Population Model for Respiratory Syncytial Virus Kinetics Using Transit Compartments Based on Human Challenge Data. Notes: Overarching Aim
. Introduction. Data. Methods. Results 5. Discussion A Population Model for Respiratory Syncytial Virus Kinetics Using Transit Compartments Based on Human Challenge Data Julia Korell,BruceGreen,DymphyHuntjens
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 25 July 2002 EMEA/ COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE
More informationB2M (Human) ELISA Kit
B2M (Human) ELISA Kit Catalog Number KA0222 96 assays Version: 02 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Background... 3 Principle of the Assay...
More informationChapter 17: Immunization & Immune Testing. 1. Immunization 2. Diagnostic Immunology
Chapter 17: Immunization & Immune Testing 1. Immunization 2. Diagnostic Immunology 1. Immunization Chapter Reading pp. 505-511 What is Immunization? A method of inducing artificial immunity by exposing
More information1. Immunization. What is Immunization? 12/9/2016. Chapter 17: Immunization & Immune Testing. 1. Immunization 2. Diagnostic Immunology
Chapter 17: Immunization & Immune Testing 1. Immunization 2. Diagnostic Immunology 1. Immunization Chapter Reading pp. 505-511 What is Immunization? A method of inducing artificial immunity by exposing
More informationICH CONSIDERATIONS Oncolytic Viruses
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ICH CONSIDERATIONS Oncolytic Viruses 20 November 2008 EMEA/CHMP/GTWP/607698/2008
More informationMedicines Control Authority Of Zimbabwe
Medicines Control Authority Of Zimbabwe BIOEQUIVALENCE APPLICATION FORM Form: EVF03 This application form is designed to facilitate information exchange between the Applicant and the MCAZ for bioequivalence
More informationFentanyl (Human) ELISA Kit
Fentanyl (Human) ELISA Kit Catalog Number KA0931 96 assays Version: 06 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Background... 3 Principle of the
More informationtrial. Key trial data points:
February 23, 2015 ADMA Biologics Announces Positive Data on Primary and Secondary Endpoints from its Pivotal Phase III Clinical Trial for RI-002 at the AAAAI Medical Conference RAMSEY, N.J., Feb. 23, 2015
More informationHuman Angiotensinogen / SerpinA8 / AGT ELISA Pair Set
Human Angiotensinogen / SerpinA8 / AGT ELISA Pair Set Catalog Number : SEK10994 To achieve the best assay results, this manual must be read carefully before using this product and the assay is run as summarized
More informationBIOPHARMACEUTICAL PROCESS EVALUATED FOR VIRAL CLEARANCE
The purpose of Viral Clearance evaluation is to assess the capability of a manufacturing production process to inactivate and/or remove potential viral contaminants. Experience and knowledge in selecting
More informationAgreed by IDWP and VWP September Adopted by CHMP 13 October Start of public consultation 26 October 2016
1 2 3 13 October 2016 EMA/CHMP/360458/2016 Committee for Human Medicinal Products (CHMP) 4 5 6 7 8 Concept paper on preparation of a guideline on the evaluation of medicinal products indicated for the
More informationHuman C-Reactive Protein / CRP ELISA Pair Set
Human C-Reactive Protein / CRP ELISA Pair Set Catalog Number : SEK11250 To achieve the best assay results, this manual must be read carefully before using this product and the assay is run as summarized
More informationHuman IL-10 ELISA MAX Set Deluxe
Human IL-10 ELISA MAX Set Deluxe Cat. No. 430604 (5 plates) 430605 (10 plates) 430606 (20 plates) ELISA Set for Accurate Cytokine Quantification from Cell Culture Supernatant, Serum, Plasma or Other Body
More informationHigh Sensitive Rat Leptin ELISA
High Sensitive Rat Leptin ELISA For the high sensitive quantitative determination of Leptin in rat serum or plasma. Cat. No. KT-379 For Research Use Only. 1 Rev. 091707 PRODUCT INFORMATION High Sensitive
More informationProphylaxis against respiratory syncytial virus (RSV), varicella, and pneumococcal infections: economic-based decision-making Strutton D R, Stang P E
Prophylaxis against respiratory syncytial virus (RSV), varicella, and pneumococcal infections: economic-based decision-making Strutton D R, Stang P E Record Status This is a critical abstract of an economic
More informationHuman high sensitivity C-Reactive protein (hs-crp) ELISA Kit
Human high sensitivity C-Reactive protein (hs-crp) ELISA Kit Catalog No. CSB-E08617h (96T) This immunoassay kit allows for the in vitro quantitative determination of human hs-crp concentrations in serum,
More informationAssayMax Human Transferrin ELISA Kit
AssayMax Human Transferrin ELISA Kit Assaypro LLC 3400 Harry S Truman Blvd St. Charles, MO 63301 T (636) 447-9175 F (636) 395-7419 www.assaypro.com For any questions regarding troubleshooting or performing
More informationRetinol Binding Protein Urinary EIA Kit
K-ASSAY KAMIYA BIOMEDICAL COMPANY KAMIYA BIOMEDICAL COMPANY Retinol Binding Protein Urinary EIA Kit For the quantitative determination of RBP in human, rat, dog and rhesus monkey urine Cat. No. KT-744
More informationS402- AAP Updated Guidelines for Palivizumab Prophylaxis
S402- AAP Updated Guidelines for Palivizumab Prophylaxis Michael T. Brady, MD Associate Medical Director Nationwide Children s Hospital Columbus, Ohio Disclosure of Relevant Relationship Dr. Brady (or
More informationCanine Creatinine(Cr) ELISA kit. Catalog No. MBS (96T)
Canine Creatinine(Cr) ELISA kit Catalog No. MBS704078 (96T) This immunoassay kit allows for the in vitro quantitative determination of canine Cr concentrations in serum, plasma and other biological fluids.
More informationDisclosure. Hemophilia: The Royal Treatment. Objectives. Background. History of Hemophilia. Epidemiology 1/4/2018
Disclosure Hemophilia: The Royal Treatment Nikki Heeren, PharmD PGY1 Resident Avera McKennan Hospital I have had no financial relationship over the past 12 months with any commercial sponsor with a vested
More informationBovine Prostaglandin E2 (PG-E2) ELISA Kit
Bovine Prostaglandin E2 (PG-E2) ELISA Kit Catalog Number. CSB-E14237B For the quantitative determination of endogenic bovine prostaglandin E2 (PG-E2) concentrations in serum, plasma, tissue homogenates.
More informationMouse IFNAR1 ELISA Pair Set
Mouse IFNAR1 ELISA Pair Set Catalog Number : SEK50469 To achieve the best assay results, this manual must be read carefully before using this product and the assay is run as summarized in the General ELISA
More informationSpecialised Services Circular
Specialised Services Circular Issue date: 11 August 2015 ID Category: Status: Public & Press: SSC1535 For Action Circulation distribution list only of Palivizumab (To reduce the risk of RSV in High Risk
More informationUser Manual. Cat. No
User Manual ELISA Amplification System Cat. No. 19589-019 Table of Contents 1. Notices to Customer... 1 1.1 Important Information... 1 1.2 Precautions... 1 2. Overview... 2 3. Methods... 4 3.1 Components...
More informationTF (Human) ELISA Kit. Catalog Number KA assays Version: 08. Intended for research use only.
TF (Human) ELISA Kit Catalog Number KA0510 96 assays Version: 08 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Background... 3 Principle of the Assay... 3 General Information...
More informationDepoVax TM : A novel delivery formulation for cancer immunotherapy and infectious disease vaccines
DepoVax TM : A novel delivery formulation for cancer immunotherapy and infectious disease vaccines May 10, 2017 The DepoVax Platform A patented oil-based formulation NOT an adjuvant Creates powerful vaccines
More informationCHAPTER 24. Immunology
CHAPTER 24 Diagnostic i Microbiology and Immunology Growth-Dependent Diagnostic Methods Isolation of Pathogens from Clinical Specimens Proper sampling and culture of a suspected pathogen is the most reliable
More informationHuman IL10RB ELISA Pair Set ( CRFB4 )
Human IL10RB ELISA Pair Set ( CRFB4 ) Catalog Number : SEK10945 To achieve the best assay results, this manual must be read carefully before using this product and the assay is run as summarized in the
More informationMouse ICAM-1 / CD54 ELISA Pair Set
Mouse ICAM-1 / CD54 ELISA Pair Set Catalog Number : SEK50440 To achieve the best assay results, this manual must be read carefully before using this product and the assay is run as summarized in the General
More informationPictArray ToRCH ELISA Kit
TORCH Instructions PictArray ToRCH ELISA Kit Instructions for testing human serum samples on PictArray ToRCH Panel consisting of Toxoplasma gondii, Rubella, Cytomegalovirus (CMV), Herpes Simplex Virus
More informationSupporting Information
Supporting Information Chan et al. 10.1073/pnas.0903849106 SI Text Protein Purification. PCSK9 proteins were expressed either transiently in 2936E cells (1), or stably in HepG2 cells. Conditioned culture
More informationCyno Monkey IgG Antigen ELISA Kit
Cyno Monkey IgG Antigen ELISA Kit Catalog No: ICYIGGKT Lot No: SAMPLE INTENDED USE This cynomolgus macaque (Macaca fascicularis) monkey Immunoglobulin G (IgG) antigen assay is intended for the quantitative
More informationpenicillin, especially in the blood, are usually too small to produce adequate zones METHODS OF MEASURING PENICILLIN CONCENTRATIONS
METHODS OF MEASURING PENICILLIN CONCENTRATIONS IN BODY FLUIDS' WILLIAM M. M. KIRBY AND LOWELL A. RANTZ The Department of Medicine, Stanford University School of Medicine, San Francisco 15, California Received
More informationHuman alpha-galactosidase A / GLA ELISA Pair Set
Human alpha-galactosidase A / GLA ELISA Pair Set Catalog Number : SEK12078 To achieve the best assay results, this manual must be read carefully before using this product and the assay is run as summarized
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Synagis (palivizumab injection) Applicable* Medical Benefit x Effective: 8/15/18 Pharmacy- Formulary 1 Next Review: 6/19 Pharmacy- Formulary 2 Date of Origin: 6/05 Pharmacy- Formulary
More informationRat ACE2 / Angiotensin- Converting Enzyme 2 ELISA Pair Set
Rat ACE2 / Angiotensin- Converting Enzyme 2 ELISA Pair Set Catalog Number : SEK80031 To achieve the best assay results, this manual must be read carefully before using this product and the assay is run
More informationBIOEQUIVALENCE TRIAL INFORMATION
PRESENTATION OF BIOEQUIVALENCE TRIAL INFORMATION BIOEQUIVALENCE TRIAL INFORMATION GENERAL INSTRUCTIONS: Please review all the instructions thoroughly and carefully prior to completing the Bioequivalence
More informationMouse IGF-1 ELISA Kit
GenWay Biotech, Inc. 6777 Nancy Ridge Drive San Diego, CA 92121 Phone: 858.458.0866 Fax: 858.458.0833 Email: sales@genwaybio.com http://www.genwaybio.com Mouse IGF-1 ELISA Kit Catalog No GWB-ZZD063 Size
More informationRat Caspase 3 (Casp-3) ELISA Kit
Rat Caspase 3 (Casp-3) ELISA Kit Catalog No. CSB-E08857r (96T) This immunoassay kit allows for the in vitro quantitative determination of rat Casp-3 concentrations in serum, plasma and other biological
More informationOfficial Letter from the DOH
Issued Date 2009/04/02 Issued by DOH Ref. No 0980316268 RE The DOH issued an official letter to announce the implementation of the Guideline for BA/BE Studies on April 2, 2009 (Ref. No. 0980316265). Please
More informationMouse Factor XII Total ELISA Kit
Mouse Factor XII Total ELISA Kit Catalog No: IMFXIIKT-TOT Lot No: SAMPLE INTENDED USE This mouse coagulation Factor XII antigen assay is intended for the quantitative determination of total Factor XII
More informationSynagis (Palivizumab) Drug Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Synagis (Palivizumab) Drug Prior Authorization Protocol This policy has been developed through review of medical
More informationARTICLE. Respiratory Syncytial Virus and Premature Infants Born at 32 Weeks Gestation or Earlier
ARTICLE Respiratory Syncytial Virus and Premature Infants Born at 32 Weeks Gestation or Earlier and Economic Implications of Prophylaxis Timothy P. Stevens, MD; Robert A. Sinkin, MD; Caroline B. Hall,
More information